24 results about "IMMUNOLOGIC DEFICIENCY" patented technology

The present invention relates to methods of treating patients with primary immunodeficiency diseases and disorders, using a CXCR4 inhibitor.

The invention discloses an IL10-secreting and BAFFR-targeting chimeric antigen receptor, a CAR-T cell and application. The IL10-secreting and BAFFR-targeting chimeric antigen receptor comprises a signal peptide region, a BAFFR-targeting antigen binding domain, a hinge region, a transmembrane structural domain, a co-stimulation structural domain, a signal transduction structural domain and human IL10 which are sequentially connected from an amino terminal to a carboxyl terminal, wherein the signal peptide region, the BAFFR-targeting antigen binding domain, the hinge region, the transmembrane structural domain, the co-stimulation structural domain, the signal transduction structural domain and the human IL10 are sequentially connected from the amino terminal to the carboxyl terminal; the co-stimulation structural domain comprises a CD28 co-stimulation structural domain and a 4-1BB co-stimulation structural domain which are connected, and the signal transduction structural domain is ITAM1 of CD3 zeta. The kit can specifically aim at autoimmune B cells, and immunodeficiency and patient infection caused by full B cell deletion are avoided. The secretion of IL10 on the CAR-T cells can reduce the depletion rate of the CAR-T cells in vivo, so that the long-acting inhibition effect on the disease process is achieved.

The invention discloses an indole styryl oxadiazole bridging compound with toxoplasma gondii resisting activity, which is formed by bridging three pharmacophores of 3-indoleacetonitrile, oxadiazole and cinnamic acid. The invention relates to the technical field of antiparasite, and has the beneficial effects that the compound provides a new chemical entity for development of toxoplasma gondii resistant drugs, opens up a new direction for design of the antiparasite drugs, has a wide application prospect, and is suitable for industrial production. Particularly, the gene has an important transformation value in the aspects of immunodeficiency patient treatment and toxoplasma gondii prevention and control in the livestock breeding industry.

A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in transplant therapy and treatment of immune deficiency and genetic disorders.

This disclosure provides IL-15 fusion proteins and compositions comprising IL-15 fusion proteins. This disclosure further provides methods for treating and / or preventing immunodeficiency in subjects, as well as methods for cancer immunotherapy, which include administering fusion proteins as described herein.

The invention relates to an efficient energy supply type laboratory mouse feed which comprises the following components in percentage by weight: 20-40% of corn, 10-30% of wheat, 1-5% of wheat middling, 4-10% of soybean meal, 2-8% of fish meal, 2-6% of chicken meal, 1-10% of soybean hull, 1-5% of soybean oil, 1-5% of lard, 0.5-2% of stone powder, 0.5-1.5% of calcium hydrophosphate, 2-5% of premix, 1-5% of MCT microcapsule powder and 0.5-2% of glutamine. The stability of MCT is improved through a microencapsulation method, the activity of glutamine is reserved through an embedding method, the synergistic effect of MCT microcapsule powder and glutamine is utilized, meanwhile, lard oil and fat raw materials are added, high-temperature steam is used for curing materials in the production process, the fragrance of the feed is further improved, the palatability of the feed is jointly improved, the food intake of laboratory mice is not affected, and the production cost is reduced. The utilization efficiency of the feed is improved; the experimental mouse feed can reduce body fat and improve blood lipid level, can effectively prolong exhaustion time of mice, and is suitable for cultivation and maintenance of special experimental animals such as intestinal injury models and immunodeficiency models.

The disclosure provides IL-15 fusion proteins as well as compositions comprising them. The disclosure further provides methods of treating and / or preventing immunodeficiency as well as methods for cancer immunotherapy in a subject, wherein the method includes administering a fusion protein as described herein.

The present disclosure is directed to a method of treating a CTLA-4 checkpoint associated immunodeficiency by administering a therapeutically effective amount of a pharmaceutical composition comprising 1H-indole-3-carboxaldehyde (3-IAld) or 1-methylindole-3-carboxylic acid.

The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating complementopathies and monitoring therapy in disease where complement inhibitors are used. In one aspect, the present invention provides a method for detecting dysregulation of the alternative pathway of complement in a patient. In one embodiment, the method comprises the steps of (a) contacting serum obtained from a patient with a composition comprising double CD46 / PIGA knockout (DKO) cells suspended in MgEGTA buffer; and (b) measuring luminescence continuously or serially over a period of time, wherein a lower luminescence related to a healthy control indicates dysregulation of the alternative pathway of complement in the patient.

The invention discloses a cholate synergistic effect-based open wound medicine formula and a preparation method thereof, cholate and sodium chloride are subjected to high-pressure homogenization and grinding to nanoscale, acetic acid, water and alcohol are sequentially added, after pH is adjusted, terminal filtration is carried out through a 0.22-micron filter membrane, sterility is ensured, the formula can penetrate into a corium layer to inhibit inflammatory factors (such as TNF-alpha), and the open wound medicine has a good application prospect. And an epidermal cell migration signal (such as TGF-beta 1) is activated, so that the healing period is shortened to 8-10 days. The nano-scale dispersion improves the medicine permeation efficiency, the weak acid environment inhibits the formation of a gram-positive bacterium biofilm, and the eye drops are free of sensitization, are suitable for immunodeficiency patients and have auxiliary effects on haemorrhoids and eye diseases.

The present invention discloses a GPAAV‑CBA‑H_TP53(P53)‑WPRE plasmid, an engineered bacterium and a preparation method, and belongs to the field of genetic engineering technology. The base sequence of the plasmid is shown in SEQ ID NO.1. The genetically engineered bacterium is obtained by transforming the plasmid into competent cells. The preparation method comprises: double enzyme digestion of the expression vector to obtain an expression vector fragment; preparation of a target gene fragment; and connection of the expression vector fragment with the target gene fragment. The present invention has the following advantages: the adeno-associated virus packaged by the plasmid has a significant inhibitory effect on the growth of human tumors when administered via the circulatory system, and the effect is better than the reference substance gemcitabine; the adeno-associated virus packaged by the plasmid has a blood sugar-lowering effect on immunodeficient subjects, and has no effect on non-immunodeficient subjects, and its blood sugar-lowering effect is correlated with the immunodeficiency of the subject.

Provided are a plurality of CpG-containing oligodeoxynucleotides (ODNs) capable of regulating the immune function of the body and the use thereof. The design concept of the sequences and structures of the oligodeoxynucleotides are different from those of a traditional type-A CpG ODN, which embodies the complex druggability rules of the oligodeoxynucleotides, and solves the druggability problem of the traditional type-A CpG. The oligodeoxynucleotides have the activity of regulating the immune function of the body both in vitro and in vivo, can stimulate the production of type I, II and III interferons, up-regulate a Th1-type immune response, and suppress Th2-type and Th17-type inflammatory responses. Therefore, the oligodeoxynucleotides can be used in the prevention and treatment of allergic diseases, including allergic rhinitis, atopic dermatitis, asthma, chronic obstructive pulmonary diseases, and diseases associated with eosinophilic granulocytes and Th17, caused by a Th2-type immune response; can be used in the prevention and treatment of the infection and transmission of respiratory or non-respiratory pathogenic microorganisms including viruses, bacteria, fungi and parasites; can be used to improve the immunity level of the elderly population and people with immunodeficiency; can be used to convert "cold tumors" into "hot tumors" and improve the effect of cancer immunotherapy; can be used in the prevention and treatment of central nervous system diseases associated with immune dysfunction such as Alzheimer's disease; and can be used for other diseases associated with immune dysfunction.

The disclosure provides IL-15 fusion proteins as well as compositions comprising them. Specifically, the fusion protein comprising at least one of an IL-15Ra sequence and / or an IL-15 sequence fused to an albumin protein. The disclosure further provides methods of treating and / or preventing immunodeficiency as well as methods for cancer immunotherapy in a subject, wherein the method includes administering a fusion protein as described herein.

The present invention relates to an immunodeficient non-human animal where endogenous drug metabolising enzymes and transcription factors are substantially inactivated. In some aspects of the invention, the animal expresses human drug metabolising enzymes and associated transcription factors. There is also provided related methods of generating the animal of the invention. Additionally, there is provided methods of performing preclinical drug studies using the animal of the invention.

The present disclosure provides IL-15 fusion proteins and compositions comprising the IL-15 fusion proteins. Specifically, the fusion protein comprises at least one of an IL-15R alpha sequence and / or an IL-15 sequence fused with an albumin protein. The disclosure also provides methods of treating and / or preventing immunodeficiency and methods for immunotherapy of cancer in a subject, wherein the methods comprise administering the fusion protein described herein.

In some aspects, the disclosure provides an immunodeficient NOD-Fcgr1null mouse that can be used to measure the pharmacokinetics and activity of human IgG antibodies, to produce human IgG antibodies, and to model human disease treatment.

The present disclosure relates methods for treating skin disorders caused by an immune deficiency with oral formulations comprising 1-((2S,5R)-5-((5-((R)-2,2-difluorocyclopropyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (Compound I) or pharmaceutically acceptable derivative thereof. In particular, the oral formulations described herein may be used to treat atopic dermatitis.

The present disclosure relates, in part, to hematopoietic stem cell (HSC) targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for delivery of nucleic acids and / or therapeutic agents to HSCs. In certain embodiments, the LNPs of the disclosure are suitable for in utero administration. In another aspect, the disclosure provides methods for treating, preventing, and / or ameliorating HSC-related disease and / or disorders, including but not limited to hemoglobinopathies and immunodeficiencies.

The invention belongs to the technical field of model animal preparation, and particularly relates to a pulmonary aspergillosis rat model construction method based on tracheal inoculation under laryngoscope direct view and application thereof. According to the invention, standardized immunosuppression is carried out on rats by using cyclophosphamide, and an immunodeficiency state conforming to a disease basis can be stably and repeatedly induced. Based on direct sight of the laryngoscope, the glottis structure of the rat is clear and visible, and the intubation process is visual and controllable. The technical threshold is obviously reduced, and the success rate and the operation repeatability of a beginner are improved; the method has the advantages that laryngeal injury and mistaken inoculation are avoided to the greatest extent, it is guaranteed that bacterial liquid is accurately fed into the trachea, neck operation wounds are avoided, non-specific inflammation interference is reduced, the uniformity, stability and repeatability of a model are improved, and the modeling success rate reaches 100%. The invention provides a disease research platform which is standardized, quantifiable, high in quality and highly associated with clinic, and can be used for screening the pulmonary aspergillosis treatment medicines and evaluating the effectiveness of the pulmonary aspergillosis treatment medicines.

The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients. systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore. SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels. these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly. the invention relates to a composition containing immunoglobulins A (IgA). more particularly secretory IgA. for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof

The present disclosure relates to methods for producing mature oocytes comprising transplanting ovarian tissue or any fragment thereof of a human female into at least one recipient site of an immunodeficient rabbit, and collecting mature oocytes from said transplanted ovarian tissue. In addition, the methods comprises providing conditions for follicles development and oocytes maturation in said rabbit.

The invention discloses a method for pre-activating neutrophil based on microfluid shear stress, and belongs to the field of biological medicine. According to the device and the method, the micro-fluidic chip is used for constructing the flow micro-channels with the reducing structures in different appearance shapes, accurate and stable flow speed control is realized by virtue of a pneumatic perfusion system, and controllable shear stress is applied to the neutrophile granulocytes through the reducing structures of the micro-fluidic chip, so that the drug-free pre-activation of the neutrophile granulocytes is realized, and the drug-free pre-activation of the neutrophile granulocytes is realized. The antibacterial functions of chemotaxis, phagocytosis, NETs formation, ROS release and the like are directionally enhanced. The activated neutrophil can be used for treating local or systemic infection through local smearing or venous transfusion, and can be used independently or combined with antibiotics. According to the method, the bacterial clearance rate in an infection model can be remarkably increased, organ injury is relieved, and immune overreaction is regulated. The invention provides a novel cellular immunotherapy for treatment of drug-resistant bacterium infection and immunodeficiency patients, and has standardized and repeatable clinical application potential.

Provided is a method for treating common variable immunodeficiency (CVID), or for treating an inflammatory-CVID condition resulting from bacterial translocation, including administering to the human patient a therapeutically effective amount of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib). Also provided is a method of inhibiting secretion of an inflammatory factor by peripheral blood mononuclear cells, including contacting the cells with rilzabrutinib.